FDA Rejects Replimune's Drug Application RP1 Amid Controversy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2026
0mins
Source: stocktwits
- FDA Drug Rejection: The FDA has once again rejected Replimune's melanoma drug RP1, citing insufficient data to provide substantial evidence of effectiveness, leading to a 13% drop in Replimune's stock on Tuesday, reflecting market pessimism about the company's future prospects.
- Commissioner Defense: FDA Commissioner Marty Makary defended the agency in an interview, asserting that there were no 'corrupt sweetheart deals' with Replimune and noted that three independent teams reached the same conclusion, indicating that the drug's effectiveness remains unclear, showcasing the FDA's rigor in the drug approval process.
- Medical Community Outcry: Doctors criticized the FDA's decision in an opinion piece in The Wall Street Journal, highlighting that the initial panel had recommended approval for RP1, which was later overturned by the then-FDA biologics chief, reflecting inconsistencies in FDA decision-making that could impact patient treatment options.
- Replimune's Counterargument: Replimune expressed dissatisfaction with the FDA's decision, with CEO Sushil Patel stating that the drug's unavailability is not due to its failure but rather the inefficiency of the regulatory system, emphasizing the company's challenging position in the drug approval process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REPL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REPL
Wall Street analysts forecast REPL stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 4.910
Low
3.00
Averages
11.43
High
18.00
Current: 4.910
Low
3.00
Averages
11.43
High
18.00
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives have engaged in securities fraud or other unlawful business practices, potentially exposing investors to significant losses.
- FDA Response Letter: On April 10, 2026, Replimune announced it received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA), indicating a disagreement with the FDA over the sufficiency of the data set supporting the application, which has impacted market confidence.
- Stock Price Plunge: Following the FDA news, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Legal Background: Pomerantz LLP is a prominent securities class action law firm with over 85 years of experience, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, highlighting the potential legal liabilities facing Replimune.
See More
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- FDA Response Letter: On April 10, 2026, Replimune announced it received a complete response letter from the FDA regarding its Biologics License Application, indicating a disagreement with the FDA over the sufficiency of the data set, which impacts the company's drug approval process.
- Stock Price Plunge: Following this announcement, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Implications: Pomerantz LLP, recognized for its expertise in securities litigation, may provide legal support to affected investors seeking to recover losses due to the company's actions, further exacerbating the crisis of confidence in Replimune.
See More
Replimune Group Faces Securities Investigation
- Investigation Launched: The Schall Law Firm has announced an investigation into Replimune Group for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- FDA Response Letter: On April 10, 2026, Replimune disclosed that it received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1 in combination with nivolumab, indicating a dispute over the suitability of submitted data.
- Stock Price Plunge: Following the negative FDA feedback, Replimune's shares plummeted nearly 64.3% on April 13, 2026, reflecting significant market concerns about the company's future prospects.
- Investor Rights Protection: The Schall Law Firm is urging affected investors to participate in the litigation, emphasizing its expertise in securities class actions and shareholder rights litigation to provide legal support for investors.
See More
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns regarding corporate governance.
- FDA Response Letter: On April 10, 2026, Replimune announced it received a Complete Response Letter (CRL) from the FDA, indicating that there was disagreement over the sufficiency of the data set supporting its Biologics License Application (BLA), which may impact future product approval plans.
- Stock Price Plunge: Following the FDA news, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting market pessimism regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP, recognized as a leading firm in securities class action litigation, has recovered numerous multimillion-dollar damages for victims of securities fraud, demonstrating its strong influence and expertise in handling such cases.
See More
FDA Commissioner's Departure Triggers Biotech Market Reactions
- Leadership Change: The departure of FDA Commissioner Marty Makary is perceived as a positive signal for the biotech sector, although analysts warn that the industry may face pressure until a permanent replacement is found, potentially leading to market volatility.
- Market Reaction: The Nasdaq biotechnology index rose 1% on Tuesday, reflecting an initial positive response from investors to Makary's exit, particularly following his public disagreements with drugmakers like Replimune and Moderna.
- Increased Uncertainty: Analysts caution that the ongoing leadership vacuum at the FDA could result in more delays and unpredictability, diminishing the agency's ability to provide guidance and credible policy commitments, thereby impacting the investability of the biopharma ecosystem.
- Stock Performance: Shares of uniQure and Replimune rose by 5% and nearly 10%, respectively, indicating market optimism regarding new leadership, although Makary's departure also introduces uncertainty within the industry.
See More
Replimune Shares Surge 30% Following FDA Leadership Change
- Significant Stock Surge: Replimune (REPL) shares rose approximately 30% on Wednesday, following the resignation of FDA Commissioner Marty Makary, indicating market optimism regarding new leadership and the company's future prospects.
- Context of Leadership Change: Makary's resignation came amid reported pressure from President Trump, reflecting turmoil within the FDA and dissatisfaction with his leadership, potentially creating favorable conditions for Replimune's RP1 therapy resubmission.
- Therapy Application Challenges: Despite Replimune's efforts to engage with the FDA through a Type A meeting prior to its RP1 therapy application, the FDA's rejection in April led to a significant drop in the company's stock, highlighting the substantial impact of FDA decisions on biopharma companies.
- Market Outlook: Investment group Galzus Research maintains a cautious buy rating on Replimune, suggesting that with Makary's departure, there is potential for RP1 resubmission, which could open new growth opportunities for the company.
See More
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives have engaged in securities fraud or other unlawful business practices, potentially exposing investors to significant losses.
- FDA Response Letter: On April 10, 2026, Replimune announced it received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA), indicating a disagreement with the FDA over the sufficiency of the data set supporting the application, which has impacted market confidence.
- Stock Price Plunge: Following the FDA news, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Legal Background: Pomerantz LLP is a prominent securities class action law firm with over 85 years of experience, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, highlighting the potential legal liabilities facing Replimune.
See More
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- FDA Response Letter: On April 10, 2026, Replimune announced it received a complete response letter from the FDA regarding its Biologics License Application, indicating a disagreement with the FDA over the sufficiency of the data set, which impacts the company's drug approval process.
- Stock Price Plunge: Following this announcement, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Implications: Pomerantz LLP, recognized for its expertise in securities litigation, may provide legal support to affected investors seeking to recover losses due to the company's actions, further exacerbating the crisis of confidence in Replimune.
See More
Replimune Group Faces Securities Investigation
- Investigation Launched: The Schall Law Firm has announced an investigation into Replimune Group for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- FDA Response Letter: On April 10, 2026, Replimune disclosed that it received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1 in combination with nivolumab, indicating a dispute over the suitability of submitted data.
- Stock Price Plunge: Following the negative FDA feedback, Replimune's shares plummeted nearly 64.3% on April 13, 2026, reflecting significant market concerns about the company's future prospects.
- Investor Rights Protection: The Schall Law Firm is urging affected investors to participate in the litigation, emphasizing its expertise in securities class actions and shareholder rights litigation to provide legal support for investors.
See More
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns regarding corporate governance.
- FDA Response Letter: On April 10, 2026, Replimune announced it received a Complete Response Letter (CRL) from the FDA, indicating that there was disagreement over the sufficiency of the data set supporting its Biologics License Application (BLA), which may impact future product approval plans.
- Stock Price Plunge: Following the FDA news, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting market pessimism regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP, recognized as a leading firm in securities class action litigation, has recovered numerous multimillion-dollar damages for victims of securities fraud, demonstrating its strong influence and expertise in handling such cases.
See More
FDA Commissioner's Departure Triggers Biotech Market Reactions
- Leadership Change: The departure of FDA Commissioner Marty Makary is perceived as a positive signal for the biotech sector, although analysts warn that the industry may face pressure until a permanent replacement is found, potentially leading to market volatility.
- Market Reaction: The Nasdaq biotechnology index rose 1% on Tuesday, reflecting an initial positive response from investors to Makary's exit, particularly following his public disagreements with drugmakers like Replimune and Moderna.
- Increased Uncertainty: Analysts caution that the ongoing leadership vacuum at the FDA could result in more delays and unpredictability, diminishing the agency's ability to provide guidance and credible policy commitments, thereby impacting the investability of the biopharma ecosystem.
- Stock Performance: Shares of uniQure and Replimune rose by 5% and nearly 10%, respectively, indicating market optimism regarding new leadership, although Makary's departure also introduces uncertainty within the industry.
See More
Replimune Shares Surge 30% Following FDA Leadership Change
- Significant Stock Surge: Replimune (REPL) shares rose approximately 30% on Wednesday, following the resignation of FDA Commissioner Marty Makary, indicating market optimism regarding new leadership and the company's future prospects.
- Context of Leadership Change: Makary's resignation came amid reported pressure from President Trump, reflecting turmoil within the FDA and dissatisfaction with his leadership, potentially creating favorable conditions for Replimune's RP1 therapy resubmission.
- Therapy Application Challenges: Despite Replimune's efforts to engage with the FDA through a Type A meeting prior to its RP1 therapy application, the FDA's rejection in April led to a significant drop in the company's stock, highlighting the substantial impact of FDA decisions on biopharma companies.
- Market Outlook: Investment group Galzus Research maintains a cautious buy rating on Replimune, suggesting that with Makary's departure, there is potential for RP1 resubmission, which could open new growth opportunities for the company.
See More
